Chapter 10: Dyslipidemia Management

Abnormal blood lipid levels represent a modifiable risk factor for atherosclerosis and coronary heart disease, making their assessment and management a cornerstone of cardiovascular prevention. Lipoproteins, the transport vehicles for lipids in circulation, differ significantly in composition and metabolic function. Chylomicrons carry dietary triglycerides from the intestine, very low-density lipoproteins transport endogenously produced triglycerides from the liver, low-density lipoproteins deliver cholesterol to peripheral tissues and correlate most strongly with coronary disease risk, and high-density lipoproteins promote reverse cholesterol transport back to the liver for excretion. Understanding these three metabolic pathways—exogenous processing of dietary fat, endogenous processing of liver-produced lipids, and nonspecific macrophage degradation—provides the foundation for recognizing how dyslipidemia develops. Screening recommendations call for fasting lipid panels every five years in adults starting at age twenty, with attention to both hereditary forms and secondary causes such as diabetes or renal disease. Risk stratification incorporates modifiable factors including smoking, obesity, and physical inactivity alongside nonmodifiable characteristics such as age and family history. Target low-density lipoprotein goals vary based on individual risk profile, ranging from less than one hundred sixty milligrams per deciliter for lower-risk individuals to less than seventy for those with advanced coronary disease. Therapeutic lifestyle change addresses the foundation through dietary modification, emphasizing reduced saturated fat intake and increased soluble fiber consumption, with pharmacotherapy added after twelve weeks if targets remain unmet. Statins function as first-line agents by inhibiting hepatic cholesterol synthesis, though alternative medications including bile acid sequestrants, nicotinic acid, and ezetimibe serve specific roles in certain patient populations. Metabolic syndrome, characterized by the concurrent presence of elevated triglycerides, reduced high-density lipoprotein, central obesity, hypertension, and glucose intolerance, substantially accelerates atherosclerosis risk. Advanced lipid analysis using electrophoresis reveals particle size patterns that predict atherogenicity more accurately than standard measurements alone. Nursing responsibilities encompass early cardiovascular screening, patient education regarding dietary and lifestyle modifications, monitoring for therapeutic efficacy and adverse effects, and assessment of potential interactions between lipid-lowering medications and complementary agents.